Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Compugen(CGEN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CGEN
09/25/2026: CGEN (5-star) is currently NOT-A-BUY. Pass it for now.
Compugen is a clinical-stage biotechnology company that utilizes a unique, AI-driven computational discovery platform to identify novel immuno-oncology targets. Its primary strength lies in its robust pipeline of candidates, including COM701, which are designed to address limitations in current cancer treatments. The investment story centers on the potential for these novel drug candidates to achieve successful clinical milestones and secure value-creating pharmaceutical partnerships. However, investors must consider the significant risks of clinical failure, lack of current revenue, and the intense competitive landscape dominated by established pharmaceutical giants. This stock is best suited for risk-tolerant, growth-oriented investors who monitor clinical trial outcomes and partnership-related news closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-growth potential linked to clinical breakthroughs but carries the substantial risk of failure inherent in early-stage biotech. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find opportunities around major clinical trial milestones or partnership announcements. |
| Value investor | Weak fit | The company lacks current profitability and established earnings, making traditional value metrics difficult to apply. |
| Dividend investor | Weak fit | Compugen does not pay dividends and is focused on R&D investment rather than returning cash to shareholders. |
| Low-risk investor | Weak fit | Biotechnology stocks are inherently volatile, especially those without approved products. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to clinical data readouts and partnership developments. |
| Valuation risk | High | Valuations are speculative and based on the probability of future success rather than current cash flows. |
| Competition risk (Immuno-oncology) | High | The company faces intense competition from better-resourced firms developing similar checkpoint inhibitor therapies. |
| Business quality | Medium | The business relies on a successful proprietary technology platform, but sustainability depends on clinical results. |
| Dividend income | Low / none | Income investors should not look to this equity for dividends. |
| Execution risk | High | Success depends on managing complex clinical trials and securing necessary funding. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 174.37% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 224.50M USD | Price to earnings Ratio 6.24 | 1Y Target Price 4.6 |
Price to earnings Ratio 6.24 | 1Y Target Price 4.6 | ||
Volume (30-day avg) 260.7K shares | Beta 2.79 | 52 Weeks Range 1.38 - 3.23 | Updated Date 09/25/2026 |
52 Weeks Range 1.38 - 3.23 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.38 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Collaboration and Licensing | Revenue from upfront fees, R&D funding, and milestone payments associated with partnerships. | Revenue is sporadic and depends on successful scientific progress and partnership deals. |
| Geography | Operations are primarily based in Israel, with global impact through international pharmaceutical partnerships. | The company has global reach through partners but remains an Israeli-based biotech firm. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 6.24 | Forward PE 12.36 | Enterprise Value 110.33M | Price to Sales(TTM) 3.03 |
Enterprise Value 110.33M | Price to Sales(TTM) 3.03 | ||
Enterprise Value to Revenue 1.49 | Enterprise Value to EBITDA 3.6 | Shares Outstanding 94.72M | Shares Floating 92.67M |
Shares Outstanding 94.72M | Shares Floating 92.67M | ||
Percent Insiders 2.1 | Percent Institutions 15.22 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Compugen
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2000-08-11 | CEO, President & Director Dr. Eran Ophir Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 75 | Website https://cgen.com |
Full time employees 75 | Website https://cgen.com | ||
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.